Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
47 hedge funds and large institutions have $26.9M invested in Galera Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 9 closing their positions.
117% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $824K
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
7% more funds holding
Funds holding: 44 → 47 (+3)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
47% less capital invested
Capital invested by funds: $50.6M → $26.9M (-$23.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.14M |
| 2 |
Two Sigma Investments
New York
|
+$416K |
| 3 |
BlackRock
New York
|
+$389K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$361K |
| 5 |
Two Sigma Advisers
New York
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.21M |
| 2 |
Morgan Stanley
New York
|
-$482K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$450K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$439K |
| 5 |
Millennium Management
New York
|
-$255K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
51
HRT Financial
New York
| – | -$97K | -21,164 | Closed |
|
|
AC
52
Aristides Capital
Louisville,
Kentucky
| – | -$92K | -20,000 | Closed |
|
|
XT
53
XTX Topco
George Town,
Cayman Islands
| – | -$62K | -13,499 | Closed |
|
54
Osaic Holdings
Scottsdale,
Arizona
| – | -$3.78K | -1,451 | -93% |
|
GRTX Hedge Fund Activity: Q1 2022 in Review
47 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q1 2022, worth a combined $26.9M — down 47% from $50.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GRTX positions and 9 closed out — a net gain of 3 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.14M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $1.21M sold.
- 47 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q1 2022, up from 44 in Q4 2021.
- Funds reported $26.9M of Galera Therapeutics, Inc. Common Stock stock for Q1 2022, down 47% quarter-over-quarter.
- 12 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q1 2022 and 9 closed out, a net change of +3 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $1.14M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q1 2022 was Acuta Capital Partners, an estimated $1.21M sold.
Based on aggregated 13F filings for Q1 2022.